Novartis announces positive phase III results showing efficacy of BAF312 in patients with secondary progressive MS - Nasdaq

Novartis announces positive phase III results showing efficacy of BAF312 in patients with secondary progressive MS Nasdaq Novartis International AG / Novartis announces positive phase III results showing efficacy of BAF312 in patients with secondary progressive MS . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content ... and more »

from Health - Google News http://news.google.com/news/url?sa=t&fd=R&ct2=us&usg=AFQjCNFHyuslpD2ltJXgQofYX5rUuEMdDg&clid=c3a7d30bb8a4878e06b80cf16b898331&cid=52779188640737&ei=1JW-V5DZJoiT3AGDq7OwCg&url=http://www.nasdaq.com/press-release/novartis-announces-positive-phase-iii-results-showing-efficacy-of-baf312-in-patients-with-secondar-20160825-00021
via IFTTT